SCHEMBL4771731

SCHEMBL4771731

Cc1ccc(-c2nc(NCCc3c[nH]c4ccccc34)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.54
CYP3A4 P08684 7/20 0.53
CYP1A2 P05177 5/20 0.53
CYP2D6 P10635 5/20 0.53
CYP2C19 P33261 5/20 0.53
CLK4 Q9HAZ1 5/20 0.53
USP2 O75604 4/20 0.53
CYP2C9 P11712 4/20 0.53
HSD17B10 Q99714 3/20 0.53
ALDH1A1 P00352 2/20 0.53
ALOX15 P16050 2/20 0.53
CDK4 P11802 2/20 0.52
CCND1 P24385 2/20 0.52
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
GAA P10253 1/20 0.47
CCNT1 O60563 1/20 0.44
CCNA2 P20248 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775877 0.90 CYP3A4 (0.56) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL3962080 0.89 CDK4 (0.58) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2241071 0.87 CYP3A4 (0.57) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2241055 0.87 CYP3A4 (0.51) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2240068 0.87 CDK4 (0.55) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2241708 0.86 GBA1 (0.57) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2240377 0.83 GBA1 (0.47) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2237738 0.82 GBA1 (0.63) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL2238361 0.82 PTGDR (0.49) GBA1CYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL11968310 0.81 GBA1 (0.49) GBA1CYP3A4CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed